Zimmer Biomet Holdings Inc (ZBH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zimmer Biomet Holdings Inc (ZBH) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($418.70 Million) by net assets ($12.77 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check ZBH PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Zimmer Biomet Holdings Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Zimmer Biomet Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Zimmer Biomet Holdings Inc (ZBH) net assets for net asset value and shareholders' equity analysis.
Zimmer Biomet Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zimmer Biomet Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Leidos Holdings Inc
NYSE:LDOS
|
0.059x |
|
Franklin Resources Inc
NYSE:BEN
|
-0.002x |
|
Emera Inc.
TO:EMA
|
0.052x |
|
Asustek Computer Inc
TW:2357
|
0.065x |
|
Falabella
SN:FALABELLA
|
0.018x |
|
Trent Limited
NSE:TRENT
|
0.247x |
|
Joint Stock Company Kaspi.kz
NASDAQ:KSPI
|
-0.507x |
|
GF Securities Co Ltd
SHE:000776
|
-0.317x |
Annual Cash Flow Conversion Efficiency for Zimmer Biomet Holdings Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Zimmer Biomet Holdings Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see Zimmer Biomet Holdings Inc (ZBH) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $12.48 Billion | $1.50 Billion | 0.120x | -5.11% |
| 2023-12-31 | $12.49 Billion | $1.58 Billion | 0.127x | +18.56% |
| 2022-12-31 | $12.03 Billion | $1.28 Billion | 0.107x | -9.75% |
| 2021-12-31 | $12.67 Billion | $1.50 Billion | 0.118x | +19.88% |
| 2020-12-31 | $12.20 Billion | $1.20 Billion | 0.099x | -22.84% |
| 2019-12-31 | $12.39 Billion | $1.59 Billion | 0.128x | -17.43% |
| 2018-12-31 | $11.28 Billion | $1.75 Billion | 0.155x | +14.93% |
| 2017-12-31 | $11.74 Billion | $1.58 Billion | 0.135x | -20.12% |
| 2016-12-31 | $9.67 Billion | $1.63 Billion | 0.169x | +94.92% |
| 2015-12-31 | $9.81 Billion | $849.80 Million | 0.087x | -46.74% |
| 2014-12-31 | $6.52 Billion | $1.06 Billion | 0.163x | +6.36% |
| 2013-12-31 | $6.30 Billion | $963.10 Million | 0.153x | -22.15% |
| 2012-12-31 | $5.87 Billion | $1.15 Billion | 0.196x | -7.99% |
| 2011-12-31 | $5.51 Billion | $1.18 Billion | 0.213x | +3.20% |
| 2010-12-31 | $5.77 Billion | $1.19 Billion | 0.207x | +4.35% |
| 2009-12-31 | $5.64 Billion | $1.12 Billion | 0.198x | +7.94% |
| 2008-12-31 | $5.65 Billion | $1.04 Billion | 0.184x | -7.68% |
| 2007-12-31 | $5.45 Billion | $1.08 Billion | 0.199x | -5.91% |
| 2006-12-31 | $4.92 Billion | $1.04 Billion | 0.211x | +12.77% |
| 2005-12-31 | $4.69 Billion | $878.20 Million | 0.187x | -14.13% |
| 2004-12-31 | $3.95 Billion | $862.20 Million | 0.218x | +38.99% |
| 2003-12-31 | $3.15 Billion | $494.80 Million | 0.157x | -73.87% |
| 2002-12-31 | $366.30 Million | $220.20 Million | 0.601x | -72.46% |
| 2001-12-31 | $78.70 Million | $171.80 Million | 2.183x | +145.16% |
| 2000-12-31 | $261.00 Million | $232.40 Million | 0.890x | +93.42% |
| 1999-12-31 | $391.00 Million | $180.00 Million | 0.460x | -- |
About Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skul… Read more